Article

How Biofilms and Amyloid May Help to Trigger Lupus

ACR2013: More familiar as a suspect in Alzheimer disease, amyloid proteins may trigger autoantibodies in lupus when introduced via infection, a mouse study suggests.

A bacterial amyloid with the endearing name of curli that forms part of microbial biofilms is implicated a possible cause of lupus in studies using a mouse model of the disease at Temple University. The link to human lupus is less than purely theoretical, say researchers in the abstract of their scheduled presentation at the American College of Rheumatology annual meeting, because humans are exposed to curli during urinary tract and gastrointestinal infections.

The controlled experiment exposed wild-type and lupus-prone NZBW F1 mice to either curli derived from Salmonella cultures or to phosphate-buffered saline, injected intraperitoneally three times a week for five weeks, and then watched for the development of autoantibodies. The team found that immune cells (bone marrow-derived dendritic cells, to be specific) responded strongly to the presence of curli, producing "large quantities" of the interleukins IL-6, IL-10, and IL-12. Dendritic cells from the lupus-prone mice overexpressed interferon-producing genes compared to wild type.

Curli synergizes with DNA in the creation of biofilms, and the lupus-prone mice produced high quantities of autoantibodies to chromatin and nucleic acid after the injections of curli.

The upshot: In lupus-susceptible humans, nucleic acid-containing bacterial amyloids ininfectious  biofilms may be an important environmental trigger for autoantibody reactions.

Related Videos
John Stone, MD, MPH: Continuing Progress With IgG4-Related Disease Research
Philip Conaghan, MBBS, PhD: Investigating NT3 Inhibition for Improving Osteoarthritis
Rheumatologists Recognize the Need to Create Pediatric Enthesitis Scoring Tool
Presence of Diffuse Cutaneous Disease Linked to Worse HRQOL in Systematic Sclerosis
Alexei Grom, MD: Exploring Safer Treatment Options for Refractory Macrophage Activation Syndrome
Jack Arnold, MBBS, clinical research fellow, University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine
John Tesser, MD, Adjunct Assistant Professor of Medicine, Midwestern University, and Arizona College of Osteopathic Medicine, and Lecturer, University of Arizona Health Sciences Center, and Arizona Arthritis & Rheumatology Associates
Gaith Noaiseh, MD: Nipocalimab Improves Disease Measures, Reduces Autoantibodies in Sjogren’s
Laure Gossec, MD, PhD: Informing Physician Treatment Choices for Psoriatic Arthritis
Søren Andreas Just, MD, PhD: Developing AI to Mitigate Rheumatologist Shortages for Disease Assessment
© 2024 MJH Life Sciences

All rights reserved.